New pill takes on tough lung cancer mutation

NCT ID NCT07668752

Recruiting now Disease control Sponsor: Genfleet Therapeutics (Shanghai) Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This phase 3 trial tests a new daily pill, GFH375, against standard chemotherapy (docetaxel) in 300 people with advanced KRAS G12D lung cancer that has worsened after prior treatments. The drug is designed to block the specific cancer-driving mutation. Participants are randomly assigned to receive either the pill or chemo, and researchers will compare how well each shrinks tumors and delays cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GFH375 (a targeted drug that blocks the KRAS G12D mutation)
What this could lead to: If successful, GFH375 could offer a more effective and less toxic treatment option for people with KRAS G12D lung cancer who have run out of standard options.
What could go wrong: This is an early look at GFH375 in a large trial; it may not prove better than chemo, and side effects are possible. The drug is still experimental.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS G12D MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KRAS G12D MUTATION NSCLC (NON-SMALL CELL LUNG CANCER)

Contacts and locations

Locations

Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 201210, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.